Drugs / Jincaopian Tablets
Jincaopian Tablets
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05460546 | Jan → Nov 2021 | chronic pain syndrome | Beijing Konruns Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05970783 | Nov 2022 → Mar 2024 overdue | chronic pain syndrome | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jincaopian Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05970783 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “ZY5301 tablets, an effective part preparation extracted from Ajuga decumbens Thunb. (jingucao), are being tested as a treatment for CPP caused by PID.” PMID 39042407 ↗ Jul 2024 |
| Route | Oral | “p.o.” NCT05970783 ↗ |